This multicenter, prospective, non-interventional study aims to evaluate data on humoral and cellular immune response generated within the COVID-19 vaccination standard in immunocompromised patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria:
* Patient is vaccinated according to the recent version of the COVID-19 vaccination standard for immunocompromised patients.
* Patient is 18 years of age or older at enrollment.
* Written informed consent from patient has been obtained prior to any study related procedures
Exclusion criteria:
• Patient is not vaccinated according to the recent version of the COVID-19 vaccination standard. Patient has a positive SARS-CoV-2 antigen test at the first visit.
Primary outcome measure(s)
Anti-Spike-IgG titers — At the end of each vaccination cycle (each cycle is 28 days) Time to an adequate immune response according to the recent version of the COVID-19 vaccination standard after repeated mRNA vaccinations
Trial sites (3)
Facility
City
Region
Status
Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation (Med. Klinik IV) Uniklinik der RWTH Aachen
Aachen
North Rhine-Westphalia
University Hospital of Cologne
Cologne
North Rhine-Westphalia
Universitätsklinikum Essen Klinik für Hämatologie und Stammzellentransplantation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.